1. Sulindac prevents carcinogen-induced intrahepatic cholangiocarcinoma formation in vivo.
- Author
-
Wentz SC, Yip-Schneider MT, Gage EA, Saxena R, Badve S, and Schmidt CM
- Subjects
- Animals, Anti-Inflammatory Agents, Non-Steroidal pharmacology, Apoptosis drug effects, Bile Duct Neoplasms chemically induced, Bile Duct Neoplasms pathology, Bile Ducts pathology, Carcinogens pharmacology, Cell Division drug effects, Cholangiocarcinoma chemically induced, Cholangiocarcinoma pathology, Cricetinae, Cyclooxygenase 1 metabolism, Cyclooxygenase 2 metabolism, Dinoprostone metabolism, Female, I-kappa B Proteins antagonists & inhibitors, I-kappa B Proteins metabolism, Mesocricetus, NF-KappaB Inhibitor alpha, Nitrosamines pharmacology, Transcription Factor RelA antagonists & inhibitors, Transcription Factor RelA metabolism, Antineoplastic Agents pharmacology, Bile Duct Neoplasms prevention & control, Bile Ducts, Intrahepatic pathology, Cholangiocarcinoma prevention & control, Sulindac pharmacology
- Abstract
Background: Intrahepatic cholangiocarcinoma (ICC) incidence and mortality are increasing in the United States and worldwide. ICC etiologies involve chronic inflammation. We hypothesize that the nonsteroidal anti-inflammatory agent sulindac may prevent ICC by targeting cyclooxygenase-1 and -2 (COX-1, -2) as well as COX-independent pathways., Materials and Methods: ICC was induced with the carcinogen N-nitrosobis(2-oxopropyl)amine (BOP) in Syrian golden hamsters. Cholangiocarcinogenesis was accelerated by a choline-deficient diet and administration of DL-ethionine and L-methionine. Hamsters were gavaged twice daily for 10 wk with vehicle or sulindac 25, 50, or 75 mg/kg/dose. Harvested livers underwent gross and histopathological examinations. Tissues were analyzed by immunostaining, Western blot, and enzyme-linked immunosorbent assay (ELISA)., Results: ICC incidence and multiplicity were decreased in sulindac treatment groups versus control (P < 0.05). In addition, ICC and nontumor lesion sizes decreased in treatment versus control animals. Proliferative indices (Ki-67 immunostaining) decreased and apoptosis (ApopTag immunostaining) increased in treatment versus control (P < 0.05). No changes in COX-1 and -2 protein levels were detected by Western blot. Furthermore, prostaglandin E(2) (PGE(2)) levels were unchanged in treatment and control serum and liver tissues (P > 0.05), suggesting that the antitumor effects of sulindac are mediated by COX-independent mechanisms. Nuclear p65 (activated NF-kappaB) immunostaining decreased (P < 0.05), and protein levels of the NF-kB inhibitor IkappaB-alpha increased in treatment versus control groups. p65 ELISA of liver extracts confirmed decreased NF-kappaB binding activity in sulindac-treated versus control animals (P < 0.05)., Conclusion: Sulindac effectively prevents experimental cholangiocarcinogenesis, in part by inhibiting the NF-kappaB pathway.
- Published
- 2009
- Full Text
- View/download PDF